FTC's Generic Market Analysis Forcing Divestures Even In Diverse Categories
This article was originally published in The Pink Sheet Daily
Hikma must divest rights to three drugs under Roxane Labs deal as Federal Trade Commission aims to preserve as many as five competitors in some markets.
You may also be interested in...
Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.
Teva’s buyout of Allergan’s generics business should end speculation about a Teva/Mylan merger. A new Sanofi/Regeneron tie-up and an AstraZeneca divestiture to Sanofi’s Genzyme unit are among the latest developments in immuno-oncology.
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.